Cost-effectiveness of allergen immunotherapy.

IF 3 4区 医学 Q2 ALLERGY Current Opinion in Allergy and Clinical Immunology Pub Date : 2024-12-01 Epub Date: 2024-10-04 DOI:10.1097/ACI.0000000000001028
Natalia Rodríguez-Otero, Elena Ramírez-Mateo, Maria Nieves Plana, Enrico Heffler, Darío Antolín-Amérigo
{"title":"Cost-effectiveness of allergen immunotherapy.","authors":"Natalia Rodríguez-Otero, Elena Ramírez-Mateo, Maria Nieves Plana, Enrico Heffler, Darío Antolín-Amérigo","doi":"10.1097/ACI.0000000000001028","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Allergic rhinitis is a relevant and global health problem affecting up to 5-50% of the general population and its prevalence is increasing due to climate change and pollution among other factors and counts among the 10 most frequent reasons for medical consultation, generating an important economic impact. Allergen immunotherapy (AIT) is the only allergy-disease-modifying treatment and there is plenty of evidence of its effectiveness with regards subcutaneous and oral routes of AIT.This narrative review article examines published literature in the last 24 months regarding the pharmacoeconomics of AIT versus standard of care treatment (SOC) for the treatment of allergic rhinitis and asthma.</p><p><strong>Recent findings: </strong>Farraia et al. assessed in 2022 subcutaneous immunotherapy (SCIT, _438/$500.28) and sublingual immunotherapy (SLIT) (_1021/$1116.19) plus symptomatic treatment versus SOC treatment in children with HDM-driven allergic asthma, measuring QALYs, decrease of medication, decrease of exacerbations and symptoms. They used the cost-effective threshold: _18 482.80 ($21 110.14), finding that AIT is cost-effective.Also, SCIT and SLIT plus symptomatic treatment was assessed versus SOC treatment in children with grass pollen allergic rhinitis. The authors concluded that SCIT (_933/$1065.67) and SLIT (_1408/ $1608.22) seem cost-effective, particularly SCIT.</p><p><strong>Summary: </strong>Allergen immunotherapy is cost-effective in the management of allergic rhinitis and asthma as compared with SOC alone. As most studies consider only during-treatment costs and no long-term benefits or preventive effects are being assessed, the real cost-effectiveness of allergen immunotherapy could be even higher.</p>","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ACI.0000000000001028","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: Allergic rhinitis is a relevant and global health problem affecting up to 5-50% of the general population and its prevalence is increasing due to climate change and pollution among other factors and counts among the 10 most frequent reasons for medical consultation, generating an important economic impact. Allergen immunotherapy (AIT) is the only allergy-disease-modifying treatment and there is plenty of evidence of its effectiveness with regards subcutaneous and oral routes of AIT.This narrative review article examines published literature in the last 24 months regarding the pharmacoeconomics of AIT versus standard of care treatment (SOC) for the treatment of allergic rhinitis and asthma.

Recent findings: Farraia et al. assessed in 2022 subcutaneous immunotherapy (SCIT, _438/$500.28) and sublingual immunotherapy (SLIT) (_1021/$1116.19) plus symptomatic treatment versus SOC treatment in children with HDM-driven allergic asthma, measuring QALYs, decrease of medication, decrease of exacerbations and symptoms. They used the cost-effective threshold: _18 482.80 ($21 110.14), finding that AIT is cost-effective.Also, SCIT and SLIT plus symptomatic treatment was assessed versus SOC treatment in children with grass pollen allergic rhinitis. The authors concluded that SCIT (_933/$1065.67) and SLIT (_1408/ $1608.22) seem cost-effective, particularly SCIT.

Summary: Allergen immunotherapy is cost-effective in the management of allergic rhinitis and asthma as compared with SOC alone. As most studies consider only during-treatment costs and no long-term benefits or preventive effects are being assessed, the real cost-effectiveness of allergen immunotherapy could be even higher.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
过敏原免疫疗法的成本效益。
审查目的:过敏性鼻炎是一个相关的全球性健康问题,影响着多达 5-50% 的普通人群,其发病率因气候变化和污染等因素而不断上升,并已跻身十大最常见的就诊原因之列,产生了重要的经济影响。过敏原免疫疗法(AIT)是唯一可改变过敏性疾病的治疗方法,有大量证据表明皮下注射和口服途径的 AIT 非常有效。这篇叙述性综述文章研究了过去 24 个月内发表的文献,内容涉及 AIT 与标准护理治疗(SOC)在治疗过敏性鼻炎和哮喘方面的药物经济学对比:Farraia 等人在 2022 年评估了皮下免疫疗法(SCIT,_438/500.28 美元)和舌下免疫疗法(SLIT)(_1021/1116.19 美元)加对症治疗与 SOC 治疗对 HDM 引起的过敏性哮喘患儿的疗效,衡量了 QALYs、用药减少量、加重和症状减少量。他们采用了成本效益阈值:此外,他们还对草花粉过敏性鼻炎患儿进行了 SCIT 和 SLIT 加对症治疗与 SOC 治疗的对比评估。作者总结道,SCIT(_933/1065.67 美元)和 SLIT(_1408/1608.22 美元)似乎具有成本效益,尤其是 SCIT。摘要:与单纯 SOC 相比,过敏原免疫疗法在过敏性鼻炎和哮喘的治疗中具有成本效益。由于大多数研究只考虑了治疗期间的成本,没有评估长期效益或预防效果,因此过敏原免疫疗法的实际成本效益可能更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.90
自引率
3.60%
发文量
109
审稿时长
6-12 weeks
期刊介绍: This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on one to three topics, every issue of Current Opinion in Allergy and Clinical Immunology delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as upper airway disease; mechanisms of allergy and adult asthma; paediatric asthma and development of atopy; food and drug allergies; and immunotherapy.
期刊最新文献
Real-world evidence of allergen immunotherapy. eHealth in pediatric respiratory allergy. Allergen-specific immunotherapy at the extremes of age: below 5 years and elderly: evidence beyond indications? Liver disease in primary antibody deficiencies. Cost-effectiveness of allergen immunotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1